Notice of Results

RNS Number : 8356N

Oxford Biomedica PLC

25 February 2009

 



	2009/OB/04
EMBARGOED UNTIL 7.00AM, 25 FEBRUARY 2009	25 FEBRUARY 2009

OXFORD BIOMEDICA: NOTICE OF FY2008 PRELIMINARY RESULTS

RESULTS DATE: 12 MARCH 2009

Oxford, UK - 25 February 2009: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announces today that it will be releasing its preliminary results for the twelve months ended 31 December 2008 on Thursday, 12 March 2009.

Analyst meeting: An analyst briefing will be held at 09:30 am on Thursday, 12 March 2009 at the offices of Buchanan Communications, 45 Moorfields, London EC2Y 9AE. 

Web cast: Simultaneously to the analyst briefing at 09:30 am, there will be a live audio web cast of the presentation. To connect to the web cast facility, please go to the Company's website: http://www.oxfordbiomedica.co.uk/ approximately 10 minutes (09:20 am) before the start of the briefing. This will also be available for replay shortly after the presentation.

-Ends-

For further information, please contact:
Oxford BioMedica plc:  John Dawson, Chief Executive Officer	Tel: [phone]
JPMorgan Cazenove Limited: James Mitford/ Gina Gibson	Tel: [phone]
City/Financial Enquiries: Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Buchanan Communications	Tel: [phone]
Scientific/Trade Press Enquiries: Sue Charles/ Holly Griffiths/ John McIntyre College Hill Life Sciences	Tel: [phone]
US Enquiries: Thomas Fechtner The Trout Group LLC	Tel: [phone]

Notes to editors

1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in cancer immunotherapy and gene-based therapies. The Company was established in 1995, as a spin-out from Oxford University, and is listed on the London Stock Exchange. The Company has a platform of gene delivery technologies, which are based on highly engineered viral systems, and a broad development pipeline. Oxford BioMedica's lead product candidates are TroVax®, a therapeutic vaccine for multiple solid cancers, in Phase III development in collaboration with sanofi-aventis; and ProSavin®, a novel gene-based treatment for Parkinson's disease, in Phase I/II development. The Company is underpinned by over 80 patent families, which represent one of the broadest patent estates in the field. Oxford BioMedica has collaborations with sanofi-aventis, Wyeth, Sigma-Aldrich, MolMed and Virxsys. Technology licensees include Biogen Idec, Merck & Co, GlaxoSmithKline and Pfizer. Further information is available at www.oxfordbiomedica.co.uk

 

END

 

 

NORZGGZZZDRGLZZ